Vector-borne disease

This Phase 2b trial tests whether a new drug, SJ733, combined with tafenoquine can cure P. vivax malaria and prevent it from returning. About 104 adults with uncomplicated malaria will receive different schedules of SJ733 plus tafenoquine, or standard chloroquine plus tafenoquine…

This study tests two doses of an experimental oral drug, LXE408, against a standard treatment (miltefosine) for localized cutaneous leishmaniasis, a parasitic skin disease. About 250 adults in the Americas will take the medicine for several weeks. The main goal is to see if the s…

This study tests a shorter, higher-dose course of primaquine to cure vivax malaria and prevent it from coming back. Current treatments take too long, so a 3-day course could make it easier for patients to complete therapy. The trial involves over 1,000 people aged 5 and older wit…

This phase 2 trial tests a new malaria vaccine (PfSPZ-LARC2) designed to stop the malaria parasite in the liver before it can cause illness. The study involves 300 healthy women of childbearing age in Mali who plan to become pregnant. Participants receive three doses of the vacci…

This early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…

This phase II trial tests a new malaria vaccine called PvRII/Matrix-M in 36 healthy Thai adults aged 20-55. Half receive the vaccine, half a placebo. After three doses, 24 volunteers will be exposed to the malaria parasite in a controlled setting to see if the vaccine reduces inf…

This study tests whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in 375 adults and adolescents aged 14 to 60. Participants will receive either the standard dose or a half-dose, and researchers will measure their immune response and safety.…

This Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune re…

This study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes…

This early-stage trial will test the SUM-101 malaria vaccine in 24 healthy adults in Tanzania who have been exposed to malaria before. Participants will receive three doses of the vaccine or a rabies control shot, then be deliberately infected with a controlled dose of malaria pa…

This early-stage trial is testing a new vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria, to check if it is safe and whether it triggers an immune…

This study tests whether adding a fractional CO₂ laser to standard Glucantime injections helps heal skin sores from leishmaniasis faster and with less scarring. About 150 adults will be randomly assigned to get either the injection alone or the injection plus laser. Researchers w…

This study tests whether the drug emetine can help people hospitalized with dengue fever. About 600 adults aged 18 to 65 will take either a low or high dose of emetine or a placebo pill for 7 days. Researchers will track if the drug reduces deaths or stops the disease from becomi…

This trial tests whether adding a fluoroquinolone antibiotic to the standard three-drug treatment helps HIV patients with a serious bacterial infection called disseminated MAC. About 124 adults will be randomly assigned to get either the standard therapy or the four-drug combo fo…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work …

This large study tests several treatments in people hospitalized with moderate or severe dengue. The goal is to find safe, affordable drugs that prevent the disease from getting worse and help patients recover faster. Over 8,800 participants across multiple sites will be enrolled…

This study tests whether combining tafenoquine with different antimalarial drugs can better prevent P. vivax malaria from coming back. About 300 adults in Thailand with uncomplicated P. vivax infection will receive one of three drug pairs and be monitored for 6 months. The goal i…

This study looks at how much of the malaria drugs primaquine and tafenoquine pass to babies through breast milk. It involves 60 breastfeeding mothers in Papua New Guinea who recently gave birth. The goal is to find a safe way to treat and prevent relapses of vivax malaria in new …

This study looks at whether a malaria drug called tafenoquine interacts with two other common malaria treatments (DHA-piperaquine and artesunate-pyronaridine) in adults with vivax malaria. About 507 participants will receive one of the combinations or a delayed treatment to compa…

This Phase 3 trial in Ethiopia will compare four different drug regimens against the standard treatment for cutaneous leishmaniasis, a parasitic skin disease. 900 patients aged 4 to 65 will be hospitalized and treated for up to 28 days, with follow-up for 6 months. The goal is to…

This study looks at how well the oral medication selexipag works over the long term for people with a specific type of lung hypertension caused by schistosomiasis (a parasitic infection). Researchers will compare patients who received selexipag as part of routine care to similar …

This study will test the safety and effectiveness of a drug called tafenoquine in 60 children with vivax malaria in Papua New Guinea. Vivax malaria can hide in the liver and come back, so the goal is to find a treatment that clears the infection completely. The children will rece…

This early study tests a gel made with the drug miltefosine for people with uncomplicated cutaneous leishmaniasis, a skin infection from a parasite. Fifteen adults will apply the gel to their sores daily for 28 days. The main goal is to see if the gel is safe and if it helps the …

This large study in Fiji tests whether a new combination of drugs (moxidectin plus two others) can safely treat three common parasitic infections: lymphatic filariasis, scabies, and strongyloidiasis. About 5,100 people will receive either the new combo or the standard treatment o…

This study evaluates two new diagnostic tests (FORTIFIEDx and DECIPHER) for detecting Ebola and Lassa viruses. Researchers will use stored blood and cheek swab samples from patients in Guinea to see how well these tests compare to the standard PCR method. The goal is to determine…

This early-stage study tests whether wearable biosensors (like a wristband or earphones) can detect malaria infection before symptoms appear. 32 healthy adults will be exposed to the malaria parasite or a placebo in a controlled setting. Researchers will compare biosensor reading…

This study tests whether a mobile app using artificial intelligence can help frontline health workers in sub-Saharan Africa better diagnose skin-related neglected tropical diseases, like leprosy and scabies. Researchers will collect images from dermatologists to train the AI, the…

This study aims to develop a new urine test for schistosomiasis, a parasitic infection. Researchers will test a nanobody-based strip on 2500 participants, comparing it to the standard microscope method. If accurate, it could offer a quick, non-invasive diagnostic tool.

This study will test a new rapid diagnostic test for plague in the Ituri province of DR Congo. Researchers will collect samples like blood, saliva, and bubo fluid from 300 people with suspected plague to see how well the new test works compared to standard lab methods. The goal i…

This study aims to validate a non-invasive malaria diagnostic tool that detects specific compounds in breath, called volatile organic compounds (VOCs), using a device called TRACE-E. Researchers will collect breath and blood samples from 200 people aged 12 and older with fever in…

This study will collect blood samples from 200 people aged 12 and older who either have or do not have dengue. The goal is to use these samples to develop and improve diagnostic tests for dengue. Participants must have symptoms consistent with dengue and cannot have been vaccinat…

This early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe …

This study tests whether giving malaria medicine to school-age children can lower malaria cases in the entire community. School children often carry the malaria parasite without symptoms and spread it to others. The trial will involve about 4,800 children in The Gambia and measur…

This study tests a new long-acting injection called MMV371 to see if it is safe and can prevent malaria. About 80 healthy people aged 12 to 50 in Rwanda will get either the study drug or a placebo. Researchers will check if the injection protects against malaria and monitor side …

This pilot study tests whether giving a malaria drug (dihydroartemisinin piperaquine) to household members of pregnant women can help prevent malaria in the mothers. About 300 participants in Uganda will receive either a single dose or monthly doses. The goal is to see if this ap…

This study tests new devices called LASER that release a chemical to repel mosquitoes, comparing them to indoor insecticide spraying and standard prevention (bed nets, vaccines). About 22,800 people in 69 Kenyan villages will take part over two years. Researchers will check malar…

This early-stage study tests a lab-made antibody called TBE025 in 18 healthy adults aged 18 to 55. The goal is to see if it is safe and how the body processes it when given through a vein. Participants receive one dose and are closely monitored for side effects. This research hel…

This study in Uganda will test whether giving children both the R21 malaria vaccine and two different malaria prevention medicines works better than the vaccine alone. About 1,290 children will take part. The goal is to see if the combination can reduce malaria cases more effecti…

This study tests whether a 20-session exercise program can improve muscle strength, reduce fatigue, and help with balance in people who had dengue or chikungunya in the last five years. Fifty-four adults will do supervised aerobic, strength, and breathing exercises twice a week. …

This study tests whether medications that calm mast cells (ketotifen and cromolyn) can safely reduce persistent symptoms like fatigue, pain, and brain fog in people who had a tick-borne illness. Fifty adults aged 21-65 will receive either one of these drugs or a standard antihist…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard doxycycline treatment can reduce long-term complaints in adults with Lyme disease. Fifty participants will take either hydroxychloroquine or a placebo twice daily for 28 days, with follow-up visits ov…

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This early-stage study will check if a new experimental drug for malaria, called GSK3772701, changes how the body processes other medications. Twenty healthy adults aged 18 to 55 will take both GSK3772701 and a common probe drug called midazolam. The goal is to see if GSK3772701 …

This study follows 50 pregnant women with Chagas disease who take or have taken nifurtimox, to see if the drug causes harm to the baby or mother. Researchers will track birth defects, pregnancy outcomes, and infant health up to 12 months old. The goal is to collect safety data, n…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This observational study will enroll 190 hospitalized adults with dengue in Bangladesh to see if a 'leaky gut' — where bacteria and toxins escape the intestines into the blood — is linked to severe disease. Researchers will measure gut leakage markers in blood, perform abdominal …

This study looks at immune cells in the skin of 40 healthy adults who have never received a yellow fever vaccine. Researchers will take small skin samples and blood to measure baseline levels of memory T cells. The goal is to understand the skin's natural immune state before vacc…

This early-stage trial will give 24 healthy adults three different malaria drugs—piperaquine, pyronaridine, and artesunate—alone and together to see how they interact. Researchers will measure drug levels in the blood and watch for side effects. The goal is to learn about safety …

This study looks at how different genetic makeups affect the way healthy adults process the malaria prevention drug tafenoquine (ARAKODA). Researchers will measure drug levels in blood and urine over time, along with safety checks. The goal is to better understand how to dose the…

This study will measure how many people in Assiut Governorate, Egypt, have schistosomiasis, a parasitic disease. Researchers will test urine and stool samples from 359 participants and ask about risk factors. The goal is to better understand the current burden of the disease in t…

This study will follow 5,160 pregnant women in France who have HIV, hepatitis B, hepatitis C, or an arbovirus infection (like Zika or dengue), along with their children, for up to 7 years. Researchers want to learn how these viruses and their treatments affect pregnancy, the moth…

This study follows 200 pregnant women in Brazil who received the chikungunya vaccine (VLA1553) during pregnancy or shortly before. Researchers will track pregnancy and infant health up to 12 weeks after birth, comparing them to a similar group of women who got routine vaccines. T…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study looks at a lung infection called NTM lung disease in South China. Researchers will review medical records of about 1,500 patients and collect samples from around 100 current patients to learn how the immune system reacts. The goal is to help doctors diagnose and manage…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…

This study aims to find out how common Borrelia arthritis is in Denmark and how it affects patients. Researchers will test blood and joint fluid from 350 adults with joint swelling to look for Borrelia bacteria. Participants will also answer questions about symptoms and tick expo…

This study looks at whether giving iron to babies with low iron helps their bodies respond better to malaria and measles vaccines. About 324 infants in Kenya will take part. The goal is to see if treating iron deficiency can improve how well the vaccines protect them.

This study looks back at 400 adults in France who had a rare but serious blood vessel infection caused by the bacteria Coxiella burnetii. The goal is to learn why some patients die within two years and how to diagnose the infection faster. Researchers will review medical records …

This study will test a new way to care for people in Ghana who have both a neglected tropical skin disease (like leprosy or Buruli ulcer) and mental health challenges like depression or anxiety. Researchers will work with 200 affected adults and local health workers to create a G…

This study will follow 4,000 children in Cambodia to understand how common Japanese Encephalitis (JE) is and how often it spreads without symptoms. Researchers will compare healthy children with those hospitalized for fever and brain-related symptoms. The goal is to measure the t…